JP2022552378A - パーキンソン病を治療するための顆粒球マクロファージコロニー刺激因子をコードするｍＲＮＡ - Google Patents

パーキンソン病を治療するための顆粒球マクロファージコロニー刺激因子をコードするｍＲＮＡ Download PDF

Info

Publication number
JP2022552378A
JP2022552378A JP2022522647A JP2022522647A JP2022552378A JP 2022552378 A JP2022552378 A JP 2022552378A JP 2022522647 A JP2022522647 A JP 2022522647A JP 2022522647 A JP2022522647 A JP 2022522647A JP 2022552378 A JP2022552378 A JP 2022552378A
Authority
JP
Japan
Prior art keywords
mir
lnp
csf
seq
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022522647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552378A5 (enExample
Inventor
エリック イー－チュン フアン，
ジャレッド イアコヴェッリ，
ピチョット， シーモア デ
ジィー－ワー ツェ，
ローリー ケニー，
キャサリン オルソン，
ハワード ゲンデルマン，
アール． リー モズレー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Publication of JP2022552378A publication Critical patent/JP2022552378A/ja
Publication of JP2022552378A5 publication Critical patent/JP2022552378A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022522647A 2019-10-15 2020-10-15 パーキンソン病を治療するための顆粒球マクロファージコロニー刺激因子をコードするｍＲＮＡ Pending JP2022552378A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962915317P 2019-10-15 2019-10-15
US62/915,317 2019-10-15
US202063013139P 2020-04-21 2020-04-21
US63/013,139 2020-04-21
PCT/US2020/055852 WO2021076811A1 (en) 2019-10-15 2020-10-15 Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease

Publications (2)

Publication Number Publication Date
JP2022552378A true JP2022552378A (ja) 2022-12-15
JP2022552378A5 JP2022552378A5 (enExample) 2023-10-24

Family

ID=73198473

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022522647A Pending JP2022552378A (ja) 2019-10-15 2020-10-15 パーキンソン病を治療するための顆粒球マクロファージコロニー刺激因子をコードするｍＲＮＡ

Country Status (6)

Country Link
US (1) US20240123034A1 (enExample)
EP (1) EP4045076A1 (enExample)
JP (1) JP2022552378A (enExample)
AU (1) AU2020366209A1 (enExample)
CA (1) CA3158013A1 (enExample)
WO (1) WO2021076811A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202214445D0 (en) * 2022-09-30 2022-11-16 Imp College Innovations Ltd Gene therapy
WO2024240962A1 (en) * 2023-05-25 2024-11-28 Ethris Gmbh Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136438A1 (ja) * 2007-04-27 2008-11-13 Kyushu University, National University Corporation 遺伝子治療用ウイルスベクター
JP2010510219A (ja) * 2006-11-17 2010-04-02 バイオジェン・アイデック・エムエイ・インコーポレイテッド アミロイド関連障害を処置するためのコロニー刺激因子の全身投与
WO2019152557A1 (en) * 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8613481D0 (en) 1986-06-04 1986-07-09 Diatech Ltd Translation of mrna
US5723332A (en) 1993-11-26 1998-03-03 British Technology Group Limited Translational enhancer DNA
US5824497A (en) 1995-02-10 1998-10-20 Mcmaster University High efficiency translation of mRNA molecules
EP2428570B1 (en) 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
DK2205618T3 (en) 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
JP5539962B2 (ja) 2008-04-25 2014-07-02 ノースウェスタン、ユニバーシティ コレステロールを隔離するのに適したナノ構造体
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
US9567398B2 (en) * 2010-11-18 2017-02-14 Merck Serono S.A. Antibody with specificity for GM-CSF (II)
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2016176330A1 (en) * 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
RS63625B1 (sr) 2016-05-18 2022-10-31 Modernatx Inc Kombinacije irnk koje kodiraju imunomodulirajuće polipeptide i njihova upotreba

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510219A (ja) * 2006-11-17 2010-04-02 バイオジェン・アイデック・エムエイ・インコーポレイテッド アミロイド関連障害を処置するためのコロニー刺激因子の全身投与
WO2008136438A1 (ja) * 2007-04-27 2008-11-13 Kyushu University, National University Corporation 遺伝子治療用ウイルスベクター
WO2019152557A1 (en) * 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRONTIERS IN AGING NEUROSCIENCE, vol. 7, JPN6024044061, 2015, pages 126 - 1, ISSN: 0005575465 *
MOLECULAR NEURODEGENERATION, vol. 13, JPN6024044060, 2018, pages 1 - 17, ISSN: 0005575466 *

Also Published As

Publication number Publication date
AU2020366209A1 (en) 2022-05-19
CA3158013A1 (en) 2021-04-22
US20240123034A1 (en) 2024-04-18
WO2021076811A1 (en) 2021-04-22
EP4045076A1 (en) 2022-08-24

Similar Documents

Publication Publication Date Title
JP7766583B2 (ja) 強化された薬剤送達のための組成物及び方法
US20230398074A1 (en) Nucleic Acid-Based Therapy of Muscular Dystrophies
CA3128215A1 (en) Methods of preparing lipid nanoparticles
JP2023531511A (ja) 半減期が延長されたｍＲＮＡ治療薬を含むＬＮＰ組成物
CA3024507A1 (en) Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
AU2018214556A1 (en) Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides
AU2017268396A1 (en) Polynucleotides encoding citrin for the treatment of citrullinemia type 2
AU2017266948A1 (en) Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
US20220251577A1 (en) Endonuclease-resistant messenger rna and uses thereof
AU2020368447A1 (en) mRNA encoding immune modulating polypeptides and uses thereof
JP2024506908A (ja) インビボ療法のためのペイロードを含むｌｎｐ組成物
JP2023527875A (ja) フェニルアラニンヒドロキシラーゼバリアント及びその使用
WO2024206835A1 (en) Circular mrna and production thereof
US20250213664A1 (en) Mrnas encoding checkpoint cancer vaccines and uses thereof
US20240123034A1 (en) Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
WO2024026475A1 (en) Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
TW202345870A (zh) 具有延長半衰期之信使核糖核酸
CN118946365A (zh) 编码检查点癌症疫苗的mRNA及其用途
JP2024528983A (ja) キメラ代謝リプログラミングポリペプチドをコードするｍＲＮＡ及びその使用
JP2024540170A (ja) インテグリンベータ－６をコードするポリヌクレオチド及びその使用方法
WO2026096575A1 (en) Mrna encoding concatemeric prame epitope polypeptide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250418